1. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients

    Journal of Cystic Fibrosis 14(2):262 (2015)

    This study aimed to determine whether antimicrobial susceptibility testing of Pseudomonas aeruginosa grown as a biofilm, rather than planktonically, improves efficacy of antibiotic treatment for pulmonary exacerbations. This was a multicenter randomized, double-blind controlled trial o...
  2. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.

    Journal of Cystic Fibrosis 14(2):262 (2015) PMID 25453872

    This study aimed to determine whether antimicrobial susceptibility testing of Pseudomonas aeruginosa grown as a biofilm, rather than planktonically, improves efficacy of antibiotic treatment for pulmonary exacerbations. This was a multicenter randomized, double-blind controlled trial of 14days o...
  3. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.

    Journal of Cystic Fibrosis 14(2):262 (2015) PMID 25453872

    This study aimed to determine whether antimicrobial susceptibility testing of Pseudomonas aeruginosa grown as a biofilm, rather than planktonically, improves efficacy of antibiotic treatment for pulmonary exacerbations. This was a multicenter randomized, double-blind controlled trial of 14 days ...
  4. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients.

    Journal of Cystic Fibrosis 14(2):262 (2015) PMID 25453872

    This study aimed to determine whether antimicrobial susceptibility testing of Pseudomonas aeruginosa grown as a biofilm, rather than planktonically, improves efficacy of antibiotic treatment for pulmonary exacerbations. This was a multicenter randomized, double-blind controlled trial of 14days o...
  5. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

    Antimicrobial Agents and Chemotherapy 59(1):711 (2015) PMID 25348526 PMCID PMC4291427

    Burkholderia cepacia complex and Stenotrophomonas maltophilia infections are associated with poor clinical outcomes in persons with cystic fibrosis (CF). The MIC50 based on planktonic growth and the biofilm concentration at which 50% of the isolates tested are inhibited (BIC50) of tobramycin wer...
  6. In Vitro Efficacy of High-Dose Tobramycin against Burkholderia cepacia Complex and Stenotrophomonas maltophilia Isolates from Cystic Fibrosis Patients.

    Antimicrobial Agents and Chemotherapy 59(1):711 (2015) PMID 25348526

    Burkholderia cepacia complex and Stenotrophomonas maltophilia infections are associated with poor clinical outcomes in persons with cystic fibrosis (CF). The MIC50 based on planktonic growth and the biofilm concentration at which 50% of the isolates tested are inhibited (BIC50) of tobramycin wer...
  7. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

    Antimicrobial Agents and Chemotherapy 59(1):711 (2015) PMID 25348526 PMCID PMC4291427

    Burkholderia cepacia complex and Stenotrophomonas maltophilia infections are associated with poor clinical outcomes in persons with cystic fibrosis (CF). The MIC50 based on planktonic growth and the biofilm concentration at which 50% of the isolates tested are inhibited (BIC50) of tobramycin wer...
  8. Histologic findings and clinical characteristics in acutely symptomatic ulcerative colitis patients with superimposed Clostridium difficile infection.

    American Journal of Clinical Pathology 140(6):831 (2013) PMID 24225751

    To examine biopsy specimens for histologic features suggestive of Clostridium difficile infection in patients with ulcerative colitis (UC). Nine patients with UC had colonic biopsy specimens taken during a symptomatic flare that coincided with positive C difficile (C difficile+) tests. Twenty-ei...
  9. ChronicStenotrophomonas maltophiliainfection and exacerbation outcomes in cystic fibrosis

    Journal of Cystic Fibrosis 11(1):8 (2012)

    Background Chronic Stenotrophomonas maltophilia infection is a risk factor for pulmonary exacerbation in cystic fibrosis (CF) but its impact on subsequent clinical outcomes is unknown. The aim of this study was to determine the effect of chronic S. maltophilia infection a...
  10. Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients

    Journal of Cystic Fibrosis (2012)

    This study aimed to determine whether antimicrobial susceptibility testing of Pseudomonas aeruginosa grown as a biofilm, rather than planktonically, improves efficacy of antibiotic treatment for pulmonary exacerbations. This was a multicenter randomized, double-blind controlled trial o...
  11. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis.

    Journal of Cystic Fibrosis 11(1):8 (2012) PMID 21849265

    Chronic Stenotrophomonas maltophilia infection is a risk factor for pulmonary exacerbation in cystic fibrosis (CF) but its impact on subsequent clinical outcomes is unknown. The aim of this study was to determine the effect of chronic S. maltophilia infection and associated antimicrobial therapy...
  12. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada.

    Clinical Infectious Diseases 37(8):1139 (2003) PMID 14523782

    Although information on efficacy and adverse drug reactions is lacking, ribavirin has been used empirically for the treatment of severe acute respiratory syndrome (SARS). We report common adverse events in 110 patients with suspected or probable SARS who were treated with ribavirin. Sixty-one pe...
  13. Severe acute respiratory syndrome: radiographic review of 40 probable cases in Toronto, Canada.

    Radiology 228(3):802 (2003) PMID 12853655

    To review radiographic findings of patients with probable severe acute respiratory syndrome (SARS) who were seen at a University of Toronto (Ontario, Canada) teaching hospital. Findings were reviewed for 40 patients who fulfilled the World Health Organization criteria for probable SARS. A templa...
  14. Human leucocyte antigen supertypes and immune susceptibility to HIV-1, implications for vaccine design

    Immunology Letters 79(1):151 (2001)

    T cell responses against HIV-1 have been identified in a number of exposed uninfected populations. We hypothesized that the ability to mount an effective T cell response is partly determined by the human leucocyte antigens (HLA) phenotype of the individual. We examined whether certain HLA s...